Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Chronic Sialorrhea Market?

The market size for chronic sialorrhea has witnessed substantial growth in the past few years. The market’s value is forecasted to increase from $0.72 billion in 2024 to $0.76 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The considerable growth during the historic period can be ascribed to factors such as the rising prevalence of neurological disorders, population growth, heightened awareness regarding the disorder, better diagnostic methods and a surging demand for non-invasive treatments.

Expectations are high for a robust increase in the chronic sialorrhea market size in the coming years, with projections indicating a growth to $0.97 billion by 2029, at a compound annual growth rate (CAGR) of 6.1%. This growth in the projected period can be linked to a rise in awareness regarding treatment options, the increasing demand for effective treatments, escalating health care costs, an upsurge in pediatric cases, and a growing market for oral gels and liquids. Key trends for the forecast period incorporate the use of telemedicine for remote patient monitoring, patient-focused care models, advancements in pharmacology, the fusion of speech and occupational therapies, and the evolution of long-lasting pharmaceuticals.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp

What Drivers Are Accelerating Expansion Of The Chronic Sialorrhea Market?

The growing incidence of neurodegenerative disorders is predicted to fuel the expansion of the chronic sialorrhea market in the future. Diseases characterized by the continual decay or death of nerve cells (neurons) in the brain and spinal cord are considered as neurodegenerative disorders. The increase in these disorders can be attributed to genetic predisposition, environmental factors, in-depth understanding of disease processes, chronic ailments, and socio-psychological factors. Chronic sialorrhea is a typical side effect of neurodegenerative disorders such as Parkinson’s disease and ALS. This condition necessitates specific treatments to prevent aspiration, improve oral function, and enhance patient comfort. For example, Parkinson’s UK, a UK-based charitable organization, reported that around 153,000 individuals in the UK had Parkinson’s in September 2023. With an aging population, this figure is expected to rise by 20% to a projected 172,000 by 2030. As a result, the growing incidence of neurodegenerative disorders is expected to propel the chronic sialorrhea market forward.

What Are The Key Segment Trends Observed In The Chronic Sialorrhea Market?

The chronic sialorrheamarket covered in this report is segmented –

1) By Treatment Type: Pharmacological Treatments; Botulinum Toxin Injections; Surgical Interventions; Medical Devices And Assistive Therapies

2) By Route Of Administration: Oral Medications; Injectable Treatments; Topical Applications

3) By Patient Population: Pediatric Patients; Adult Patients

4) By End-User: Hospitals And Specialty Clinics; Rehabilitation Centers; Homecare Settings

Subsegments:

1) By Pharmacological Treatments: Anticholinergic Medications; Antidepressants; Alpha-adrenergic Agonists; Salivary Gland Modulators

2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox); Botulinum Toxin Type B (Myobloc); Localized Salivary Gland Injections

3) By Surgical Interventions: Sialendoscopy; Salivary Gland Duct Dilation or Stenting; Parotid Duct Surgery; Submandibular Gland Removal (Sialadenectomy)

4) By Medical Devices And Assistive Therapies: Oral Dryness Devices; Salivary Stimulation Devices; Lip and Mouth Exercises; Artificial Salivary Glands

Which Disruptive Trends Are Driving Change Across The Chronic Sialorrhea Market?

Leading organizations in the chronic sialorrhea market are striving to develop unconventional treatments, including oral remedies, in an effort to increase patient cooperation and offer non-invasive options for managing chronic sialorrhea in children. They aim to enhance safety and efficiency while minimizing side effects. An oral solution refers to a liquid drug meant for oral usage, which includes the therapeutic ingredient dissolved in a solvent for simple ingestion. For example, in February 2023, Proveca Pharma Ltd., a pharmaceutical firm based in the UK, introduced Sialanar (glycopyrronium bromide) in France. This drug is designed to treat severe chronic sialorrhea in children suffering from neurological problems. A standout feature of this product is its liquid configuration, which ensures easy administration and accurate dosage, making it quite effective for children who find it difficult to take solid drugs. The drug has a solid record of safety and efficacy, aimed at improving the quality of life by mitigating excessive drooling, a common issue in neurodevelopmental disorders such as cerebral palsy.

Who Are The Major Stakeholders Operating In The Chronic Sialorrhea Market?

Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report

What Regional Factors Are Accelerating Growth In The Chronic Sialorrhea Market?

North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21149&type=smp

Browse Through More Reports Similar to the Global Chronic Sialorrhea Market 2025, By The Business Research Company

Chronic Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model